Product Program year 2025 Source: CMS Open Payments

Rebyota

Biological Gastroenterology

NDC 55566-9800-2

Open in the dashboard

General payments

$2,327,023

19,072 payments

Research payments

$2,414,595

414 payments

Through program year 2025, $2,327,023 in general payments and $2,414,595 in research payments were reported against Rebyota (Gastroenterology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2025 General $252,335 3,040
2025 Research $594,626 174
2024 General $358,859 4,206
2024 Research $1,364,028 205
2023 General $1,715,830 11,826
2023 Research $455,941 35

Breakdown

Who paid General payments · program years 2023–2025
  1. Ferring Pharmaceuticals Inc. $2,100,071 19,023 payments
  2. Rebiotix Inc. $150,913 29 payments
  3. Ferring Microbiome Inc. $51,415 14 payments
  4. Ferring Pharmaceuticals AS $14,680 3 payments
  5. Ferring International Center SA $7,155 2 payments
  6. Ferring Inc. $2,790 1 payment
Top recipients General payments · program year 2025
  1. Paul Feuerstadt Gastroenterology · Hamden, CT $32,516 13% · 27 payments
  2. Colleen Kraft Infectious Disease · Atlanta, GA $30,000 12% · 10 payments
  3. Anurag Maheshwari Gastroenterology · Baltimore, MD $22,737 9% · 26 payments
  4. Arthur Jeng Infectious Disease · Sylmar, CA $13,961 6% · 35 payments
  5. Cleveland Clinic Hospital Teaching hospital · OH $12,600 5% · 4 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Gastroenterology Internal Medicine $101,574 47% · 696 practitioners
  2. Infectious Disease Internal Medicine $64,348 30% · 201 practitioners
  3. Internal Medicine $10,668 5% · 145 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $8,996 4% · 181 practitioners
  5. Physician Assistant, Medical Physician Assistant $7,462 3% · 69 practitioners

The top 5 of 61 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Connecticut $34,068 14% · 52 recipients
  2. Georgia $33,738 13% · 88 recipients
  3. California $30,623 12% · 115 recipients
  4. Maryland $23,457 9% · 27 recipients
  5. Texas $22,510 9% · 210 recipients

The top 5 of 47 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to REBYOTA
Billing code Providers Services Paid by Medicare
Fecal microbiota, live - jslm, 1 ml J1440 1 2,100 $104,064

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

19,072 general · 414 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record